Kiek dividendų moka Quest Diagnostics 2025?
Pagal paskutinę informaciją nuo rugpjūtis 2025, Quest Diagnostics per paskutinius 12 mėnesių mokėjo bendrą dividendą, kuris sudarė 3,00 USD už akciją. Esant dabartiniam Quest Diagnostics kursui 178,50 USD, tai atitinka 1,68 % dividendų grąžą.
Dividendai mokami 4 kartus per metus.
1,68 % Dividendo grąža | = | 3,00 USD Dividendas | 178,50 USD akcijų kaina |
|
Ar Quest Diagnostics dividendai yra saugūs?
Quest Diagnostics kasmet didina dividendus jau 9 metus.
Per pastaruosius 10 metus Quest Diagnostics kasmet 8,556 % padidėjo.
Per 5 metų laikotarpį augo išmokos padidėjo 7,191 %.
Analitikai prognozuoja, kad einamaisiais verslo metais Dividendų didinimas bus 3,280%.
Quest Diagnostics Aktienanalyse
Ką daro Quest Diagnostics?
Quest Diagnostics Inc is a leading company in the field of diagnostic information and services, headquartered in New Jersey, USA. The company is dedicated to providing medical professionals and patients worldwide with fast, accurate, and preventive diagnostic tests.
The history of Quest Diagnostics dates back to 1967 when the company MetPath was founded by Dr. Paul A. Brown. In the following years, several acquisitions and mergers took place, eventually leading to the establishment of Quest Diagnostics in 1996. Since then, the company has continuously evolved and now offers a wide range of diagnostic tests and services, ranging from the analysis of blood samples to genetic testing procedures.
The business model of Quest Diagnostics is based on providing high-quality and individualized information to medical professionals and patients to assist in the diagnosis, treatment, and cure of their health problems. The company works closely with doctors, hospitals, and other medical institutions worldwide to offer a comprehensive range of innovative diagnostic products, procedures, and technologies tailored to meet specific needs.
Quest Diagnostics offers a wide range of services, ranging from laboratory testing to data management and clinical trials. The company has various business segments, including the Diagnostic Services business, the Medical Research Services business, and the Information Services business.
In the field of Diagnostic Services, Quest Diagnostics offers a broad spectrum of laboratory tests divided into different categories such as cancer diagnostics, cardiology, endocrinology, immunology, and infectious diseases. The company also provides a variety of genetic tests that enable precise analysis of individual genomes, supporting the diagnosis and treatment of various genetic disorders.
In the medical research field, Quest Diagnostics provides a range of services to support clinical trials and drug development. The company also offers a wide range of laboratory tests used in biomedical research to improve people's health and well-being.
The Information Services business segment of Quest Diagnostics mainly focuses on providing innovative solutions in the field of data management and information technology. This includes the development of software tools that can be used for the analysis and management of health data. Additionally, the company offers consulting services to help medical professionals address challenges related to information processing and data integration.
Quest Diagnostics is a company based on innovation and knowledge that collaborates closely with doctors, clinics, and other medical facilities worldwide to offer a relatively comprehensive range of need-specific diagnostic products, procedures, and solutions. From cancer diagnostics to genomic diagnostics, from clinical trials to information and data services, and a wide range of molecular diagnostic tests and laboratory analyses, Quest Diagnostics provides top-notch solutions for optimal patient care, contributing to the goal of improving global healthcare for people worldwide. Quest Diagnostics yra viena populiariausių įmonių Eulerpool.com svetainėje.Akcijų taupymo planai siūlo patrauklią galimybę investuotojams ilgalaikėje perspektyvoje kurti turtą. Vienas pagrindinių privalumų yra vadinamasis vidutinės išlaidos efektas: reguliariai investuojant fiksuotą sumą į akcijas arba akcijų fondus, automatiškai perkama daugiau dalinių vertybių popierių, kai kainos yra žemos, ir mažiau – kai jos aukštos. Tai gali lemti palankesnę vidutinę dalies kainą per laiką. Be to, akcijų taupymo planai suteikia galimybę ir smulkiesiems investuotojams patekti į brangias akcijas, nes jie gali dalyvauti jau su mažomis sumomis. Reguliarus investavimas taip pat skatina disciplinuotą investavimo strategiją ir padeda išvengti emociškai pagrįstų sprendimų, pavyzdžiui, impulsyvaus pirkimo ar pardavimo. Be to, investuotojai gauna naudos iš potencialaus akcijų vertės augimo bei iš dividendų, kurie gali būti reinvestuoti, kas sustiprina sudėtinio palūkanų efektą ir taip skatina investuoto kapitalo augimą.